

Helen Giza

Chief Executive Officer

Member of the Management Board since: November 1, 2019

Appointed until: May 15, 2027

Personal data:

Born: 1968
Gender: Female
Nationality: British / U.S.

Education: Chartered Certified Accountant (Great Britain)

Master of Business Administration

Kellogg School of Management, Northwestern University, Evanston, Illinois,

U.S.

Professional experience:

Fresenius Medical Care AG1

2022 - present	Chief Executive Officer and Chairwoman of the Management Board
2022 - 2023	acting Chief Financial Officer
2021 - 2022	Chief Transformation Officer
2019 - 2022	Chief Financial Officer

Takeda Pharmaceuticals Company Limited

2018 – 2019	Chief Integration & Divestiture Management Officer
2015 - 2018	Senior Vice President, Chief Financial Officer – U.S. Business Unit
2008 - 2015	Vice President, Chief Financial Officer – U.S. Business Unit

TAP Pharmaceutical Products Inc.

2005 – 2008	Vice President & Division Controller
2004 - 2005	Assistant Controller

Abbott Laboratories

2003 - 2004	Area Controller Commercial – Asia Pacific Region
1999 - 2003	Finance Manager – Manufacturing Operations

Dana Incorporated

1996 – 1999 Finance Direc	tor
---------------------------	-----

ITT, Inc.

1991 – 1996 Cost Accountant

Membership in supervisory board or comparable supervisory bodies:²

Board of Directors

Fresenius Medical Care Holdings, Inc., U.S.³ Resonetics, LLC, U.S.

Board of Administration

Vifor Fresenius Medical Care Renal Pharma Ltd., Switzerland

¹ For the period until the change of the legal form of the Company from Fresenius Medical Care AG & Co. KGaA to Fresenius Medical Care AG, the information relates to the activity as a member of the Management Board of Fresenius Medical Care Management AG in its function as General Partner of the Company at that time.

² Non-executive Director. Unless stated otherwise, the companies are not public.

³ Fresenius Medical Care Group mandate